Discussion
A single infusion of the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) was sufficient to control disease activity in most multiple myeloma patients who…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
GSK‘s Blenrep (belantamab mafodotin) cut the risk of cancer progression nearly in half compared with bortezomib when used in combination with other therapies to…
Discussion
The U.S. Food and Drug Administration (FDA) has granted priority review to Sanofi’s application of Sarclisa (isatuximab) in combination with standard of care for…
Discussion
Once-weekly induction therapy with bortezomib is as efficient as the standard two times a week dosing in people newly diagnosed with multiple myeloma, a…
Discussion
Arcellx and Kite Pharma are planning to launch a Phase 3 clinical trial, dubbed iMMagine-3, to test their cell therapy anitocabtagene…
Discussion
NXC-201, an investigational CAR T-cell therapy, has been designated an orphan drug in the European Union (EU) as a potential treatment of multiple myeloma.
